Overview

The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial

Status:
Recruiting

Trial end date:
2021-02-14

Target enrollment:

Participant gender:

Summary

This study include cancer patients who had received chemotherapy that include cisplatin. Patients were randomly assigned to either a mannitol 20 g intravenous single dose after cisplatin or a placebo (saline). The primary outcome was to compare acute kidney injury (AKI), which was defined as increase creatinine 0.3 mg/dl in 48 hours by KDIGO criteria using serum creatinine and 24 hour urine creatinine to calculated.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Phramongkutklao College of Medicine and Hospital

Treatments:

Cisplatin
Mannitol